GEN News Highlights: Feb 6, 2012

Long-Lived Nuclear Channel Proteins Implicated in Aging, CNS Disorders

(Page 1 of 1)

    Damage to extremely long-lived proteins (ELLPs) that form transport channels into the nuclei of neurons could represent a key factor in the progression of aging and potentially age-related neurodegenerative disorders such as Alzheimer disease and Parkinson disease, researchers claim. A team at the Salk Institute has found that while nearly all proteins in the human proteome are recycled every few days to prevent functional deterioration and the accumulation of damage, ELLPs are not regularly turned over, and the nuclear pore complex ELLPs identified by the Salk researchers actually appear to last an entire lifetime.

    The phenomenon means that as these ELLPs become damaged or deteriorate over time, the channels they form may become compromised, and start letting in DNA-damaging toxins that effect changes in DNA expression associated with age-related disorders.

    “The fundamental defining feature of aging is an overall decline in the functional capacity of various organs such as the heart and the brain,” comments Martin Hetzer, Ph.D., lead investigator at the Salk’s molecular and cell biology laboratory. “Our results suggest that nuclear pore deterioration might be a general aging mechanism leading to age-related defects in nuclear function, such as the loss of youthful gene expression programs.”

    Dr. Hetzer’s team says it is the only research group in the world looking specifically at the role of nuclear pore complex proteins in the aging process. The latest work is published in Science, in a paper titled “Extremely Long-Lived Nuclear Pore Proteins in the Rat Brain.”


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll